An MMP-9 exclusive neutralizing antibody attenuates blood-brain barrier breakdown in mice with stroke and reduces stroke patient-derived MMP-9 activity.
Level 5 - mechanism / opinion, no new human data
Animal models and ex vivo human sample assays
PubMed 36893823 · doi:10.1016/j.phrs.2023.106720
What was done
The authors evaluated L13, a human IgG monoclonal antibody with exclusive neutralizing specificity for matrix metalloproteinase 9 (MMP-9), in mouse models of cerebral ischemia-reperfusion and intracranial hemorrhage. Outcomes included brain tissue injury, neurological scores, blood-brain barrier breakdown, and degradation of basement membrane and endothelial tight junction proteins compared to control IgG and across wild-type versus Mmp9 knockout mice. Ex vivo assays evaluated L13 neutralization of MMP-9 enzymatic activity in sera and peri-hematoma brain tissue samples from ischemic and hemorrhagic stroke patients.
What was found
The abstract reports no numerical values, effect sizes, or sample sizes. Treatment with L13 at reperfusion onset or post-hemorrhage significantly reduced brain injury and improved neurological outcomes in wild-type mice, attenuating blood-brain barrier breakdown to an extent comparable to Mmp9 genetic deletion. These protective effects were completely absent in Mmp9 knockout mice. Ex vivo co-incubation with L13 significantly neutralized human MMP-9 activity in stroke patient sera and hemorrhagic stroke brain tissues.
Why it matters
Broad-spectrum MMP inhibitors have failed clinically due to low specificity and toxicity. Demonstrating targeted in vivo neuroprotection and ex vivo neutralization of human stroke-derived MMP-9 provides preclinical support for highly selective MMP-9 antibody therapy.
Limits
The study is limited to rodent models and ex vivo human biospecimens, leaving in vivo human safety, dosing, and efficacy unexamined. The abstract does not provide animal or human sample sizes, numerical data, effect magnitudes, or therapeutic window analyses beyond administration at reperfusion onset.
Cited by
- supports MMP-9 breaks down endothelial tight junctions and degrades the vascular basement membrane, causing blood-brain barrier leakage.